Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Cardiac events reduced by half for with prostate cancer drug

bs_subtitle

A recent paper published in European Urology, the official journal of the European Association of Urology, indicates that the gonadotropin releasing hormone (GnRH) antagonist degarelix (brand name: FIRMAGON®), may halve the relative risk of cardiovascular (CV) events and death in men with pre-existing CV disease (CVD) compared to treatment with commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists.  The report is based on a pooled analysis of 2,328 men with prostate cancer from six prospective, randomised trials.  Study co-author Jan Nilsson MD, Department of Clinical Sciences, Lund University, Sweden, said, €œOne recent study suggests that cardiovascular disease is among the most

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy